Paul Morrissey, MD
Surgery · Providence, RINPI 1134101850
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,264 of the $1,407 with a category attached, or 89.8%. 8 manufacturers reported payments, led by Veloxis Pharmaceuticals, Inc. at 37.9% of the total.
Across 16 payments — averaging $87.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$534
- Calliditas Therapeutics US Inc.$231
- Sanofi-aventis U.S. LLC$201
- Vantive US Healthcare LLC$116
- Amgen$104
- E.r. Squibb & Sons, L.L.C.$101
- plus $120 from 2 others
What the payments were for
- Food & beverage$1,26490%
- Education$14310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 5 | $534 |
| Calliditas Therapeutics US Inc. | 2 | $231 |
| Sanofi-aventis U.S. LLC | 2 | $201 |
| Vantive US Healthcare LLC | 1 | $116 |
| Amgen | 1 | $104 |
| E.r. Squibb & Sons, L.L.C. | 1 | $101 |
| AstraZeneca | 2 | $99 |
| Lemaitre Vascular, Inc. | 2 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$695
- TARPEYO$231
- THYMOGLOBULIN$129
- Renal - PD$116
- Parsabiv$104
- NULOJIX$101
How this compares
$1,407 in reported general payments places this provider in the 55th percentile of 108 surgery providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $11,999 |
| Mycophenolic AcidMycophenolate Sodium | 30 | $11,959 |
| Valganciclovir Hcl | 36 | $7,987 |
| Tacrolimus | 26 | $5,649 |
| Prednisone | 313 | $1,196 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 196 | $1,119 |
| Pantoprazole Sodium | 171 | $948 |
| Famotidine | 73 | $674 |
| Nystatin | 21 | $591 |
| Amlodipine Besylate | 98 | $586 |
| Calcitriol | 13 | $312 |
| Atorvastatin Calcium | 42 | $307 |
| Labetalol Hcl | 11 | $301 |
| Nifedipine ErNifedipine | 15 | $274 |
| Levetiracetam | 12 | $104 |
Paid to pharmacies, not to this prescriber.
Other surgery in Providence
- Joseph EspatProvidence$159K
- Marcoandrea GiorgiProvidence$63K
- Andrew LuhrsProvidence$51K
- Tristen ChunProvidence$22K
- William CioffiProvidence$18K
- Ponnandai SomasundarProvidence$10K
- Michael ConnollyProvidence$9K
- Erin FullerProvidence$7K
- Thach PhamProvidence$7K
- David EdmonsonProvidence$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.